Nucleai: $33m AI tech expansion funding
AI-powered spatial biology company Nucleai reportedly has closed a $33m USD Series B funding round, led by Sanofi Ventures and Section 32. The funding reportedly will be used to further develop the company’s platform and expand its commercial footprint.
“Nucleai’s vision is to bring spatial biology to the forefront of precision medicine and to embed the use of our platform in every clinical trial involving tissue over the next few years,” said Avi Veidman, CEO of Nucleai. “We are pleased to bring world-class investors who share our passion and vision to transform drug development and clinical treatment decisions by combining artificial intelligence, big data, spatial biology, and a comprehensive software platform.”
